MBX Biosciences, Inc. Common Stock
Price Action
Technical Summary
STAGE 2 UPTRENDMBX Biosciences, Inc. Common Stock is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 30% provides fundamental context to the price action. However, with RSI at 81, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $37.59 | +39.17% | ABOVE |
| 50 SMA | $34.71 | +50.71% | ABOVE |
| 100 SMA | $33.64 | +55.48% | ABOVE |
| 150 SMA | $33.46 | +56.31% | ABOVE |
| 200 SMA | $29.47 | +77.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MBX in an uptrend right now?
MBX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, MBX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is MBX overbought or oversold?
MBX's RSI (14) is 81. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is MBX outperforming the market?
MBX has a Relative Strength (RS) Rating of 96 out of 99. Yes, MBX is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is MBX in its 52-week range?
MBX is trading at $52.31, which is 98% of its 52-week high ($53.51) and 97% above its 52-week low ($9.63).
How volatile is MBX?
MBX has a Beta of 1.34 and 52-week volatility of 91%. It's more volatile than the S&P 500 - expect bigger swings.